H. R. 2365 
One Hundred Eighteenth Congress 
of the 
United States of America 
AT THE SECOND SESSION 
Begun and held at the City of Washington on Wednesday, 
the third day of January, two thousand and twenty-four 
An Act 
To direct the Secretary of Health and Human Services to carry out a national 
project to prevent, diagnose, treat, and cure Parkinson’s, to be known as the 
National Parkinson’s Project, and for other purposes. 
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Dr. Emmanuel Bilirakis and 
Honorable Jennifer Wexton National Plan to End Parkinson’s Act’’. 
SEC. 2. NATIONAL PARKINSON’S PROJECT. 
Title III of the Public Health Service Act (42 U.S.C. 241 et 
seq.) is amended by adding at the end: 
‘‘PART W—PARKINSON’S AND RELATED 
DISORDERS 
‘‘SEC. 399OO. NATIONAL PARKINSON’S PROJECT. 
‘‘(a) DEFINITION
OF PARKINSON’S.—In this section, the term 
‘Parkinson’s’ means— 
‘‘(1) Parkinson’s disease; and 
‘‘(2) all other neurodegenerative Parkinsonisms, including 
multiple system atrophy, corticobasal degeneration, progressive 
supranuclear palsy, and Parkinson’s-related dementia. 
‘‘(b) ESTABLISHMENT.—The Secretary shall carry out a national 
project, to be known as the National Parkinson’s Project (referred 
to in this section as the ‘Project’), to prevent, diagnose, treat, 
and cure Parkinson’s. 
‘‘(c) ACTIVITIES CARRIED OUT THROUGH PROJECT.—In carrying 
out the Project, the Secretary shall— 
‘‘(1) create, maintain, and periodically update an integrated 
national plan to prevent, diagnose, treat, and cure Parkinson’s, 
ameliorate symptoms, and slow or stop progression; 
‘‘(2) carry out the annual assessment under subsection 
(d); 
‘‘(3) provide information, including— 
‘‘(A) an estimate of the level of current Federal invest-
ment in preventing, diagnosing, treating, and curing 
Parkinson’s, ameliorating symptoms, and slowing or stop-
ping progression; and 
‘‘(B) if applicable, an estimate of the investment nec-
essary to prevent, diagnose, treat, and cure Parkinson’s, 
ameliorate symptoms, and slow or stop progression;
H. R. 2365—2 
‘‘(4) coordinate research and services across all Federal 
agencies related to Parkinson’s; 
‘‘(5) encourage the development of safe and effective treat-
ments, strategies, and other approaches to prevent, diagnose, 
treat, and cure Parkinson’s, ameliorate symptoms, and slow 
or stop progression; 
‘‘(6) improve the— 
‘‘(A) early diagnosis of Parkinson’s; and 
‘‘(B) coordination of the care and treatment of individ-
uals with Parkinson’s; 
‘‘(7) review the impact of Parkinson’s on the physical, 
mental, and social health of individuals living with Parkinson’s 
and their caregivers and families; 
‘‘(8) coordinate with international bodies, to the extent pos-
sible, to integrate and inform the mission to prevent, diagnose, 
treat, and cure Parkinson’s, ameliorate symptoms, and slow 
or stop progression globally; and 
‘‘(9) to the extent practicable, collaborate with other entities 
to prevent duplication of existing research activities for related 
disorders. 
‘‘(d) ANNUAL ASSESSMENT.—Not later than 24 months after 
the date of enactment of this section, and annually thereafter, 
the Secretary shall carry out an assessment of the Nation’s progress 
in preparing for, and responding to, the escalating burden of Parkin-
son’s, including— 
‘‘(1) recommendations for priority actions based on the 
assessment; 
‘‘(2) a description of any steps that are planned or have 
already been taken to implement such recommendations, 
including whether such recommendations can be implemented 
under existing law; and 
‘‘(3) such other items as the Secretary determines appro-
priate. 
‘‘(e) ADVISORY COUNCIL.— 
‘‘(1) IN GENERAL.—The Secretary shall establish and main-
tain an Advisory Council on Parkinson’s Research, Care, and 
Services (referred to in this section as the ‘Advisory Council’) 
to advise the Secretary on Parkinson’s-related issues. 
‘‘(2) MEMBERSHIP.— 
‘‘(A) FEDERAL MEMBERS.—The Advisory Council shall 
be comprised of experts, to be appointed by the Secretary, 
who collectively are from various backgrounds and perspec-
tives, including at least one member from each of— 
‘‘(i) the Centers for Disease Control and Preven-
tion; 
‘‘(ii) the Administration on Community Living; 
‘‘(iii) the Centers for Medicare & Medicaid Services; 
‘‘(iv) the National Institutes of Health; 
‘‘(v) the Agency for Healthcare Research and 
Quality; 
‘‘(vi) the Department of Veterans Affairs; 
‘‘(vii) the Food and Drug Administration; 
‘‘(viii) the National Science Foundation; 
‘‘(ix) the Department of Defense; 
‘‘(x) the Environmental Protection Agency; 
‘‘(xi) the Office of Minority Health; 
‘‘(xii) the Indian Health Service;
H. R. 2365—3 
‘‘(xiii) the Office of the Surgeon General of the 
Public Health Service; and 
‘‘(xiv) other relevant Federal departments and 
agencies as determined by the Secretary. 
‘‘(B) NON-FEDERAL MEMBERS.—In addition to the mem-
bers listed in subparagraph (A), the Advisory Council shall 
include 10 expert members, to be appointed by the Sec-
retary, who shall include representatives of minority 
communities, communities disproportionately affected by 
Parkinson’s, and communities underrepresented in Parkin-
son’s research, who shall each be from outside the Federal 
Government, and who shall include— 
‘‘(i) 2 Parkinson’s patient advocates, at least 1 
of whom is living with young-onset Parkinson’s; 
‘‘(ii) 1 Parkinson’s family caregiver; 
‘‘(iii) 1 health care provider; 
‘‘(iv) 2 biomedical researchers with Parkinson’s- 
related expertise in basic, translational, clinical, or 
drug development science; 
‘‘(v) 1 movement disorder specialist who treats 
Parkinson’s patients; 
‘‘(vi) 1 dementia specialist who treats Parkinson’s 
patients; and 
‘‘(vii) 2 representatives from nonprofit organiza-
tions that have demonstrated experience in Parkin-
son’s-related research or Parkinson’s-related patient 
care and other services. 
‘‘(C) REPRESENTATION.—The Secretary shall ensure 
that the members of the Advisory Council are collectively 
representative of agencies, professions, individuals, and 
entities concerned with, or affected by, activities under 
this section. 
‘‘(3) MEETINGS.— 
‘‘(A) FREQUENCY.—The Advisory Council shall meet— 
‘‘(i) at least once each quarter during the 2-year 
period beginning on the date on which the Advisory 
Council is established; and 
‘‘(ii) at the Secretary’s discretion after such period. 
‘‘(B) ANNUAL RESEARCH MEETING.—Not later than 24 
months after the date of enactment of this section, and 
every year thereafter, the Advisory Council shall convene 
a meeting of Federal and non-Federal organizations to 
discuss Parkinson’s research. 
‘‘(C) OPEN MEETINGS.—The meetings under subpara-
graphs (A) and (B) shall be open to the public. 
‘‘(4) ANNUAL REPORT.—Not later than 18 months after the 
date of enactment of this section, and every year thereafter, 
the Advisory Council shall provide to the Secretary and Con-
gress a report containing— 
‘‘(A) a list of all federally-funded efforts in Parkinson’s 
research, prevention, diagnosis, treatment, clinical care, 
and institutional-, home-, and community-based programs 
and the outcomes of such efforts; 
‘‘(B) recommendations for priority actions to expand, 
eliminate, coordinate, refocus, streamline, or condense Fed-
eral programs based on each program’s performance, mis-
sion, scope, and purpose;
H. R. 2365—4 
‘‘(C) recommendations to— 
‘‘(i) reduce the financial impact of Parkinson’s on 
families living with Parkinson’s; 
‘‘(ii) improve health outcomes for, and the quality 
of life of, individuals living with Parkinson’s; 
‘‘(iii) prevent Parkinson’s, ameliorate symptoms, 
and slow or stop progression; 
‘‘(iv) improve the quality of care provided to bene-
ficiaries with Parkinson’s who receive coverage through 
a federally-funded health care program, such as the 
Medicare program under title XVIII of the Social Secu-
rity Act or the Medicaid program under title XIX of 
such Act; 
‘‘(v) research the association between environ-
mental triggers and Parkinson’s to help reduce expo-
sure to potential triggers; and 
‘‘(vi) research and better understand the under-
lying factors contributing to Parkinson’s; 
‘‘(D) priority actions to improve all federally-funded 
efforts in Parkinson’s research, prevention, diagnosis, treat-
ment, clinical care, and institutional-, home-, and commu-
nity-based programs; 
‘‘(E) an evaluation of the implementation, including 
outcomes, of the national plan under subsection (c)(1); and 
‘‘(F) implementation steps to address the recommenda-
tions and priority actions under subparagraphs (B), (C), 
and (D), based in part on the evaluation under subpara-
graph (E). 
‘‘(5) TERMINATION.—The Advisory Council shall terminate 
at the end of calendar year 2035. 
‘‘(f) INFORMATION SHARING.—Each Federal department and 
agency that has information relating to Parkinson’s shall share 
such information with the Secretary consistent with the statutory 
obligations of such department or agency regarding disclosure of 
information, as necessary to enable the Secretary to complete a 
report under subsection (e)(4). 
‘‘(g) SUNSET.—The section shall cease to be effective at the 
end of calendar year 2035.’’. 
Speaker of the House of Representatives. 
Vice President of the United States and
President of the Senate.